Condition
Interleukin-3 Receptor Subunit Alpha Positive
Total Trials
2
Recruiting
0
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
P 1 (1)
P 2 (1)
Trial Status
Withdrawn1
Active Not Recruiting1
Clinical Trials (2)
Showing 2 of 2 trials
NCT02159495Phase 1Active Not Recruiting
Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm
NCT03739606Phase 2Withdrawn
Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer
Showing all 2 trials